Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Zotepina para la esquizofrenia

Información

DOI:
https://doi.org/10.1002/14651858.CD001948.pub2Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 18 octubre 2006see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Esquizofrenia

Copyright:
  1. Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Prasanna DeSilva

    Correspondencia a: Whitby, UK

    [email protected]

  • Mark Fenton

    Database of Uncertainties about the Effects of Treatments (DUETs), National Institute for Health and Clinical Excellence, Manchester, UK

  • John Rathbone

    HEDS, ScHARR, The University of Sheffield, Sheffield, UK

Contributions of authors

John Rathbone ‐ selected and acquired studies, extracted data and inputted data, summated data, wrote report (2006 update).

Mark Fenton ‐ prepared protocol, undertook searches, selected and acquired studies, extracted data, summated data, produced report.

Susan Morris ‐ prepared protocol, undertook searches, selected and acquired studies, extracted data, summated data, produced report.

Prasanna DeSilva ‐ prepared protocol, extracted data, produced report.

Anne‐Marie Bagnall ‐ prepared protocol, undertook searches, selected and acquired studies, extracted data, summated data, produced report.

Stephen Cooper ‐ provided comments on final version of the review.

Gert Gammelin ‐ translation of German studies, data extraction, report writing.

Maria Leitner ‐ finding funding, initial input into the protocol and searches.

Sources of support

Internal sources

  • Centre for Reviews and Dissemination, University of York, UK.

  • South Tees Community and Mental Health Services Trust, UK.

  • The Queen's University of Belfast, UK.

  • Cochrane Schizophrenia Group, UK.

External sources

  • NHS‐R&D Health Technology Assessment Programme, UK.

  • Centre for Reviews and Dissemination, University of York, UK.

Declarations of interest

Mark Fenton has lead Jansen, Lilly and Zeneca sponsored workshops for clinicians.

Prasanna De‐Silva has received financial assistance to attend various scientific meetings and conferences world‐wide.

Stephen Cooper has undertaken trials of zotepine with employees of Knoll Pharmaceuticals.

The Cochrane Schizophrenia Group has received general support funding from Eli Lilly during the years 1996‐8 (see Group Module). This, along with some funds from other pharmaceutical companies, is used to support any ongoing work of the editorial base and is not linked to any particular review (annual report available on request).

Acknowledgements

We would like to thank Maria Leitner for work undertaken at the Centre for Reviews and Dissemination, York, assisting in applying for funding for a series of reviews on the atypical antipsychotics, and input into the selection of studies. Thank you also to Daniela Domler and Melanie Rösch for help with translation.

We would like to thank Anne‐Marie Bagnall, Gert Gammelin, Susan Morriss, Maria Leitner and Steve Cooper for their contribution in previous versions of this review.

Thanks are made to Dr Martyn Corby from Orion Pharmaceuticals and Dr Chris Reynolds, Clinical Research Manager, CNS Clinical Development from Knoll/BASF.

Version history

Published

Title

Stage

Authors

Version

2006 Oct 18

Zotepine for schizophrenia

Review

Prasanna DeSilva, Mark Fenton, John Rathbone

https://doi.org/10.1002/14651858.CD001948.pub2

2000 Jan 24

Zotepine for schizophrenia

Review

Susan Morris, Anne‐Marie Bagnall, Stephen J Cooper, Prasanna DeSilva, Mark Fenton, Gert O Gammelin, Maria Leitner

https://doi.org/10.1002/14651858.CD001948

Notes

Cochrane Schizophrenia Group internal peer review complete (see Module).
External peer review scheduled.